Los Angeles Capital Management & Equity Research Inc. reduced its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 18.1% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,982 shares of the medical equipment provider’s stock after selling 1,103 shares during the period. Los Angeles Capital Management & Equity Research Inc.’s holdings in Zimmer Biomet Holdings were worth $608,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Alpha Windward LLC raised its position in Zimmer Biomet Holdings by 1.1% in the first quarter. Alpha Windward LLC now owns 1,651 shares of the medical equipment provider’s stock worth $202,000 after buying an additional 18 shares during the period. Parkside Financial Bank & Trust raised its position in Zimmer Biomet Holdings by 2.7% in the first quarter. Parkside Financial Bank & Trust now owns 839 shares of the medical equipment provider’s stock worth $102,000 after buying an additional 22 shares during the period. Enterprise Financial Services Corp raised its position in Zimmer Biomet Holdings by 1.0% in the first quarter. Enterprise Financial Services Corp now owns 2,637 shares of the medical equipment provider’s stock worth $322,000 after buying an additional 27 shares during the period. Raymond James Trust N.A. raised its position in Zimmer Biomet Holdings by 0.3% in the first quarter. Raymond James Trust N.A. now owns 8,985 shares of the medical equipment provider’s stock worth $1,097,000 after buying an additional 31 shares during the period. Finally, Wedbush Securities Inc. raised its position in Zimmer Biomet Holdings by 2.1% in the first quarter. Wedbush Securities Inc. now owns 2,459 shares of the medical equipment provider’s stock worth $300,000 after buying an additional 50 shares during the period. 84.63% of the stock is owned by hedge funds and other institutional investors.

Institutional Ownership by Quarter for Zimmer Biomet Holdings (NYSE:ZBH)

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) opened at 125.92 on Friday. The stock’s 50 day moving average price is $120.97 and its 200-day moving average price is $116.09. The company has a market cap of $25.39 billion, a PE ratio of 51.54 and a beta of 1.23. Zimmer Biomet Holdings, Inc. has a 1-year low of $95.63 and a 1-year high of $133.21.

Zimmer Biomet Holdings (NYSE:ZBH) last released its quarterly earnings results on Thursday, April 27th. The medical equipment provider reported $2.13 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.11 by $0.02. The firm had revenue of $1.98 billion for the quarter, compared to analyst estimates of $1.96 billion. Zimmer Biomet Holdings had a net margin of 6.36% and a return on equity of 16.80%. The business’s revenue for the quarter was up 3.8% compared to the same quarter last year. During the same quarter in the previous year, the company earned $2.00 EPS. On average, analysts forecast that Zimmer Biomet Holdings, Inc. will post $8.54 earnings per share for the current year.

The company also recently declared a quarterly dividend, which will be paid on Friday, July 28th. Stockholders of record on Friday, June 23rd will be given a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a dividend yield of 0.76%. The ex-dividend date of this dividend is Wednesday, June 21st. Zimmer Biomet Holdings’s payout ratio is presently 39.67%.

COPYRIGHT VIOLATION WARNING: “Zimmer Biomet Holdings, Inc. (ZBH) Position Reduced by Los Angeles Capital Management & Equity Research Inc.” was posted by Watch List News and is the sole property of of Watch List News. If you are viewing this piece of content on another publication, it was illegally copied and reposted in violation of United States & international copyright laws. The original version of this piece of content can be read at https://www.watchlistnews.com/zimmer-biomet-holdings-inc-zbh-position-reduced-by-los-angeles-capital-management-equity-research-inc/1372115.html.

A number of equities analysts have recently weighed in on the company. Citigroup Inc. upped their price objective on Zimmer Biomet Holdings from $108.00 to $130.00 and gave the stock a “neutral” rating in a research note on Friday, June 9th. ValuEngine downgraded Zimmer Biomet Holdings from a “buy” rating to a “hold” rating in a research report on Friday, June 2nd. Oppenheimer Holdings, Inc. set a $132.00 target price on Zimmer Biomet Holdings and gave the stock a “buy” rating in a research report on Friday, April 28th. Needham & Company LLC boosted their target price on Zimmer Biomet Holdings from $151.00 to $153.00 and gave the stock a “strong-buy” rating in a research report on Friday, April 28th. Finally, Zacks Investment Research downgraded Zimmer Biomet Holdings from a “hold” rating to a “sell” rating in a research report on Tuesday, April 4th. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. Zimmer Biomet Holdings currently has an average rating of “Buy” and a consensus price target of $135.88.

In other Zimmer Biomet Holdings news, insider David C. Dvorak sold 1,040 shares of the business’s stock in a transaction that occurred on Monday, March 20th. The stock was sold at an average price of $121.63, for a total value of $126,495.20. Following the sale, the insider now owns 294,077 shares of the company’s stock, valued at $35,768,585.51. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Sang Yi sold 17,731 shares of the business’s stock in a transaction that occurred on Monday, June 12th. The shares were sold at an average price of $124.56, for a total value of $2,208,573.36. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 112,302 shares of company stock worth $13,230,422. Corporate insiders own 1.07% of the company’s stock.

Zimmer Biomet Holdings Company Profile

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings, Inc. (NYSE:ZBH).

Receive News & Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.